TABLE 1.
Patient's baseline characteristics and previous therapy
| Overall, N = 171 | DRd, N = 133 | DVd, N = 38 | |
|---|---|---|---|
| Median age, years (range) | 64 (37–83) | 64 (38–79) | 64 (37–79) |
| Male, n (%) | 91 (53) | 69 (52) | 22 (58) |
| Female, n (%) | 80 (47) | 64 (48) | 16 (42) |
| eastern cooperative oncology group (ECOG) 0, n (%) | 139 (89) | 112 (90) | 27 (87) |
| ISS III, n (%) | 36 (24) | 26 (22) | 10 (33) |
| Bone lesions, n (%) | 108 (71) | 85 (72) | 23 (66) |
| hemoglobin (Hb), median (range) | 10.9 (6.9–16.7) | 11 (6.9–15.9) | 10.5 (8–16.7) |
| Creatinine, median (range) | 0.9 (0.4–7.4) | 0.9 (0.4–5.3) | 0.9 (0.54–7.4) |
| Clearance creatinine <60 ml/min/1.73m2 | 21 | 15 | 6 |
| lactate dehydrogenase (LDH), median (range) | 191 (72–574) | 189 (72–574) | 266 (114–429) |
| ASCT I° line, n (%) | 78 (46) | 61 (88) | 17 (94) |
| ASCT II° line, n (%) | 9 (5) | 8 (12) | 1 (5,6) |
| Median number of previous lines of therapy, n (range) | 1 (1–5) | 1 (1–5) | 1 (1–5) |
| Median time from diagnosis to starting DRd−DVd therapy (months), n (range) | 41 (3–305) | 37 (3–221) | 52 (3–305) |
| Daratumumab line of therapy, n (%) | |||
| II | 120 (70) | 105 (79) | 15 (39) |
| III | 32 (19) | 17 (13) | 15 (39) |
| IV+ | 19 (11) | 11 (8.3) | 8 (21) |
| Proteasome inhibitors exposed, n (%) | 146 (85) | 125 (93) | 21 (55) |
| Immunomodulatory drugs exposed, n (%) | 100 (58) | 65 (49) | 35 (92) |
Abbreviations: ASCT, autologous hematopoietic stem‐cells transplantation; ISS, international staging system.